Hybrid immunity offers increased protection that is longer-lasting against Covid-19 reinfection, studies show

Pfizer/BioNTech's Covid-19 mRNA vaccine provides an added layer of protection against reinfection for people who have been previously infected with Covid-19, as well as increased immune durability over time, according to two studies published Wednesday in the New England Journal of Medicine. The studies offer more insight into the concept of hybrid immunity: when previously infected people, who have 'natural immunity,' then get vaccine-acquired immunity. One of the studies, conducted out of Israel, found that amongst people who had recovered from Covid-19 infections, reinfections were over four times more common in those who did not receive vaccines than in those who did after the primary infection.